Navin Jacob
Stock Analyst at UBS
(2.81)
# 1,725
Out of 4,759 analysts
27
Total ratings
64.29%
Success rate
18.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Navin Jacob
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $181 → $190 | $214.29 | -11.34% | 13 | Feb 3, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $363 | $869.58 | -58.26% | 8 | Sep 22, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | $51 | $33.01 | +54.50% | 1 | Nov 9, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $117.41 | - | 1 | Apr 27, 2020 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $92 | $94.65 | -2.80% | 4 | Apr 13, 2020 |
AbbVie
Feb 3, 2025
Maintains: Neutral
Price Target: $181 → $190
Current: $214.29
Upside: -11.34%
Eli Lilly and Company
Sep 22, 2022
Upgrades: Buy
Price Target: $363
Current: $869.58
Upside: -58.26%
Royalty Pharma
Nov 9, 2020
Upgrades: Buy
Price Target: $51
Current: $33.01
Upside: +54.50%
Gilead Sciences
Apr 27, 2020
Downgrades: Neutral
Price Target: n/a
Current: $117.41
Upside: -
Merck & Co.
Apr 13, 2020
Maintains: Buy
Price Target: $96 → $92
Current: $94.65
Upside: -2.80%